Marine-Based Drugs Face Choppy Waters, But 13 Compounds In Clinical Trials
Executive Summary
When an FDA advisory committee voted against approval of Yondelis (trabectedin) for treatment of relapsed ovarian cancer, drug sponsor Centocor/Ortho Biotech wasn't the only one that was disappointed. Researchers focused on marine natural products have been tracking Yondelis, one of the leading sea-based compounds, and its clearance in the U.S. would have been a boon for their field